Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Artivion, Inc. (NYSE:AORT) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $44.8333.

Several research analysts recently weighed in on AORT shares. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Needham & Company LLC restated a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group upped their price objective on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Artivion Price Performance

NYSE AORT opened at $27.07 on Tuesday. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -386.66 and a beta of 1.24. The company’s 50 day moving average is $25.20 and its two-hundred day moving average is $29.96.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, research analysts anticipate that Artivion will post 0.45 earnings per share for the current year.

Insiders Place Their Bets

In other Artivion news, CEO James P. Mackin sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 114,978 shares of company stock worth $2,965,155 in the last three months. 6.30% of the stock is owned by company insiders.

Institutional Trading of Artivion

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the 3rd quarter valued at about $27,000. Rockefeller Capital Management L.P. increased its holdings in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Artivion during the fourth quarter valued at approximately $79,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.